What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LTG-321 is a novel, orally bioavailable, small molecule NaV1.8 inhibitor being developed as a non-opioid analgesic product”In the company’s words, NCT07915947 on ClinicalTrials.gov
- Tested for
- PK Drug-drug Interaction Study
- Main trialPhase 1
- “This Phase 1, single-center, open-label, randomized, parallel-group study will evaluate the effect of itraconazole on the PK of LTG-321 and its metabolite(s), and the safety and tolerability of LTG-321 administered alone and in combination with itraconazole, in healthy participants.”In the company’s words, NCT07915947 on ClinicalTrials.gov
Coming up1
- 24 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 24 Dec 2026 | LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study | |
| Phase 1Completed | 8 Mar 2026 | Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026